Microbial preparation for treating inflammatory bowel disease
By using a microbial preparation containing Clostridium radix spores, diarrhea, malnutrition and weight loss caused by inflammatory bowel disease in pets was solved, and the effects of improved intestinal function and weight gain were achieved.
Patent Information
- Application Number
- CN202411869622.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-18
- Publication Date
- 2025-06-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
When pets suffer from inflammatory bowel disease, they often show diarrhea, malnutrition and weight loss, and the prior art is difficult to effectively alleviate these symptoms.
A microbial preparation, including Clostridium trangiformis microecological preparation, enzymatic chicken liver powder, glutamine, fructose oligosaccharide, β-1,3-D-glucan, maltodextrin, silica and magnesium stearate, was prepared as the main component of the preparation by specific culture media and treatment methods.
This microbial preparation can effectively relieve the symptoms of diarrhea in pets, improve intestinal function, and improve the absorption and metabolism of nutrients, resulting in varying degrees of weight increase, significantly improving the health of pets with chronic intestinal diseases.
Smart Images

Figure CN120078813A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pet disease treatment, and particularly relates to a microbial preparation for treating inflammatory bowel disease. Background Art
[0002] We found that with the increasingly in-depth research on the enterohepatic axis in recent years, the correlation between bile acid metabolism and intestinal diseases has gradually attracted attention. Bile acid metabolism is closely related to the intestinal flora. Bile acids can affect the composition of intestinal microorganisms. Conversely, intestinal microorganisms can also affect the total amount and composition of the bile acid pool, thereby regulating whole-body metabolism. Patients with liver diseases such as liver disease, fibrosis, and cirrhosis usually show intestinal dysbiosis, which is characterized by a large increase in the abundance of bacteria such as Enterobacter, Enterococcus, and Clostridium, increasing the synthesis of secondary bile acids. On the contrary, individuals with intestinal diseases (such as inflammatory bowel disease) often have intestinal dysbiosis, which is characterized by a decrease in microbial diversity and a decrease in the abundance of Firmicutes bacteria, resulting in a decrease in the level of secondary bile acids and an increase in the level of conjugated bile acids in the intestine.
[0003] In addition, researchers have found that a strain of Clostridium bacteria named Clostridium hiratsukae has extremely high primary bile acid decarboxylase activity. This strain is preserved in the Guangdong Provincial Microbial Culture Collection Center with the preservation number GDMCC1.1530. Combining the in-depth research and popularization of the enterohepatic axis research and the research on second-generation probiotics in recent years, Clostridium hiratsukae obviously has the characteristics of second-generation probiotics and can be used for the treatment of inflammatory bowel disease in dogs and cats. At the same time, as a microorganism of the genus Clostridium, it can produce spores under environmental stress and germinate again when the environment is suitable. Therefore, Clostridium hiratsukae has the characteristics of becoming a commercial microecological preparation for daily use by pets. Summary of the Invention
[0004] Therefore, the object of the present invention is to provide a microbial preparation for treating inflammatory bowel disease, and its purpose is to relieve the diarrhea symptoms of pets, and at the same time relieve the malnutrition caused by diseases in pets for a long time and increase the weight of pets.
[0005] To solve the above technical problems, the present invention provides the following technical solution: A microbial preparation for treating inflammatory bowel disease, which is made from the following raw materials in parts by weight: 3-5 parts of Clostridium hiratsukae microecological preparation, 30-35 parts of enzymatically hydrolyzed chicken liver powder, 10-15 parts of glutamine, 8-10 parts of fructooligosaccharide, 10-15 parts of β-1,3-D-glucan, 39.5-40 parts of maltodextrin, 0.2-0.5 parts of silicon dioxide, and 0.5-1 part of magnesium stearate;
[0006] The Clostridium hiratsukae is the Clostridium hiratsukae strain purchased from the Guangdong Provincial Microbial Culture Collection Center with the preservation number GDMCC1.1530.
[0007] As a preferred embodiment of the microbial preparation for treating inflammatory bowel disease according to the present invention, wherein: the Clostridium hiratsukae strain is cultured in a PY medium containing glucose under anaerobic conditions.
[0008] As a preferred embodiment of the microbial preparation for treating inflammatory bowel disease according to the present invention, wherein: the PY medium containing glucose is prepared in the following proportions: 20 parts of multivalent peptone, 5 parts of yeast extract, 5 parts of sodium chloride, 5 parts of glucose, and 1000 parts of water, and the pH value is adjusted to 6.8 - 7.0.
[0009] As a preferred embodiment of the microbial preparation for treating inflammatory bowel disease according to the present invention, wherein: after the PY medium containing glucose is prepared and heated to dissolve uniformly, it is sterilized under high pressure at 121 °C for 15 min. After cooling to 37 °C, the Clostridium hiratsukae strain (GDMCC1.1530) is inoculated, and then the temperature is maintained at 37 °C and cultured under anaerobic conditions for 48 hours. After the culture is completed, it is expanded using the PYG medium.
[0010] As a preferred embodiment of the microbial preparation for treating inflammatory bowel disease according to the present invention, wherein: the PYG medium is prepared in the following proportions: 20 parts of peptone, 5 parts of glucose, 10 parts of yeast extract powder, 0.08 parts of sodium chloride, 0.5 parts of cysteine hydrochloride, 0.008 parts of calcium chloride, 0.008 parts of magnesium sulfate, 0.008 parts of potassium dihydrogen phosphate, 0.4 parts of sodium bicarbonate, and 520 parts of water, and the pH value is adjusted to 7.1 - 7.3. After the PYG medium is prepared, it is sterilized under high pressure at 115 °C for 15 minutes and cooled to 50 °C for standby.
[0011] As a preferred embodiment of the microbial preparation for treating inflammatory bowel disease according to the present invention, wherein: according to the proportion of adding 0.5 ml of vitamin K1 ethanol solution and 2.5 ml of hemin solution to every 556.1 g of PYG medium, the vitamin K1 ethanol solution and hemin solution are added to the PYG culture solution at 50 °C and mixed evenly, and then cooled to 37 °C. The culture of Clostridium hiratsukae in the PY medium is transferred into the PYG culture solution mixed with the vitamin K1 ethanol solution and hemin solution, and then two-stage culture is carried out. The first stage condition is to control the temperature at 37 °C and maintain anaerobic conditions for 72 hours.
[0012] As a preferred embodiment of the microbial preparation for treating inflammatory bowel disease according to the present invention, wherein: the preparation method of the vitamin K1 ethanol solution: weigh and prepare according to the mass ratio of vitamin K1: absolute ethanol = 1:78, filter and sterilize after dissolution for standby.
[0013] As a preferred embodiment of the microbial preparation for treating inflammatory bowel disease according to the present invention, wherein: the preparation method of the hemin solution: weigh 1 part of hemin, dissolve it in 2 times the mass of a 1 mol / L sodium hydroxide solution, add 100 parts of distilled water, sterilize it under high pressure at 121 °C for 15 min, and then cool it for standby.
[0014] As a preferred embodiment of the microbial preparation for treating inflammatory bowel disease according to the present invention, wherein: the rice husk powder is sterilized under high pressure at 121 °C for 60 min. After cooling, it is added to the culture solution after the first-stage culture according to a ratio of 8%, and cultured at 37 °C for 36 hours as the condition for the second-stage culture. After the culture is completed, the solid matter is filtered out by a filter press, and the solid matter is taken for freeze-drying to obtain the spores of Clostridium hiranonis as the finished product of the Clostridium hiranonis microecological preparation.
[0015] As a preferred embodiment of the microbial preparation for treating inflammatory bowel disease according to the present invention, wherein: the Clostridium hiranonis microecological preparation, enzymatically hydrolyzed chicken liver powder, glutamine, fructooligosaccharide, β-1,3-D-glucan, maltodextrin, silicon dioxide, and magnesium stearate are mixed, and then granulated and dried, and then tableted using a tableting machine to obtain the microbial preparation for treating inflammatory bowel disease.
[0016] The beneficial effects of the present invention: Through experiments on the preparation of the microbial preparation and based on the intuitive performance of the experimental data, the diarrhea symptoms of the test pets have been alleviated to varying degrees, which can directly reflect that their intestinal functions have been improved to varying degrees. Since the absorption and metabolism functions of the intestine for nutrients have been improved, the malnutrition of the test pets caused by diseases for a long time has been alleviated, and their weights have increased to varying degrees. Therefore, from the perspective of the actual application effect, this microbial preparation has a positive effect on pets suffering from chronic enteropathy. Description of the Drawings
[0017] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for the description of the embodiments will be briefly introduced below. Obviously, the drawings in the following description are only some embodiments of the present invention. For those of ordinary skill in the art, other drawings can be obtained based on these drawings without creative efforts. Among them:
[0018] Figure 1 It is a schematic diagram of the fecal water assessment method for the embodiment of the microbial preparation for treating inflammatory bowel disease according to the present invention.
[0019] Figure 2 It is a table for preparing the proportion of PY medium containing glucose for the microbial preparation for treating inflammatory bowel disease according to the present invention. Detailed Embodiments
[0020] To make the above objects, features, and advantages of the present invention more obvious and understandable, the following provides a detailed description of the specific embodiments of the present invention in conjunction with the accompanying drawings of the specification.
[0021] In the following description, many specific details are set forth to fully understand the present invention. However, the present invention can also be implemented in other ways different from those described herein. Those skilled in the art can make similar generalizations without departing from the connotation of the present invention. Therefore, the present invention is not limited by the specific embodiments disclosed below.
[0022] Refer to Figure 1-2 , an embodiment of the present invention provides a microbial preparation for treating inflammatory bowel disease. This microbial preparation for treating inflammatory bowel disease is made from the following raw materials in parts by weight: Clostridium hiratsukanum microecological preparation 3 - 5 parts, enzymatically hydrolyzed chicken liver powder 30 - 35 parts, glutamine 10 - 15 parts, fructooligosaccharide 8 - 10 parts, β-1,3-D-glucan 10 - 15 parts, maltodextrin 39.5 - 40 parts, silicon dioxide 0.2 - 0.5 parts, and magnesium stearate 0.5 - 1 part;
[0023] The Clostridium hiratsukanum is the Clostridium hiratsukanum strain with the preservation number GDMCC1.1530 purchased from the Guangdong Provincial Microbial Culture Collection Center.
[0024] The Clostridium hiratsukanum strain is cultured in a PY medium containing glucose under anaerobic conditions.
[0025] The PY medium containing glucose is prepared according to the following ratio: polypeptone 20 parts, yeast extract 5 parts, sodium chloride 5 parts, glucose 5 parts, and water 1000 parts, and the pH value is adjusted to 6.8 - 7.0. (Refer to Figure 2 )
[0026] After the PY medium containing glucose is prepared, it is heated and dissolved evenly, sterilized at 121 °C under high pressure for 15 min, inoculated with the Clostridium hiratsukanum strain (GDMCC1.1530) after cooling to 37 °C, then maintained at 37 °C, and cultured under anaerobic conditions for 48 hours. After the culture is completed, it is expanded with the PYG medium.
[0027] The PYG medium is prepared according to the following ratio: peptone 20 parts, glucose 5 parts, yeast extract powder 10 parts, sodium chloride 0.08 parts, cysteine hydrochloride 0.5 parts, calcium chloride 0.008 parts, magnesium sulfate 0.008 parts, potassium dihydrogen phosphate 0.008 parts, sodium bicarbonate 0.4 parts, and water 520 parts, and the pH value is adjusted to 7.1 - 7.3. After the PYG medium is prepared, it is sterilized at 115 °C under high pressure for 15 minutes and cooled to 50 °C for standby.
[0028] Add vitamin K1 ethanol solution and hemin solution to the PYG culture medium at 50 °C in the ratio of adding 0.5 ml of vitamin K1 ethanol solution and 2.5 ml of hemin solution per 556.1 g of PYG culture medium, mix well, and then cool to 37 °C. Transfer the culture of Clostridium hiranonis in PYG medium into the PYG culture medium mixed with vitamin K1 ethanol solution and hemin solution, and then carry out two-stage culture. The condition of the first stage is to control the temperature at 37 °C and maintain anaerobic conditions for 72 hours.
[0029] Preparation method of vitamin K1 ethanol solution: Weigh and prepare according to the mass ratio of vitamin K1: absolute ethanol = 1:78, filter and sterilize after dissolution for standby.
[0030] Preparation method of hemin solution: Weigh 1 part of hemin and dissolve it in 2 times the mass of 1 mol / L sodium hydroxide solution, add 100 parts of distilled water, sterilize at 121 °C under high pressure for 15 min, and then cool for standby.
[0031] Sterilize the rice husk powder at 121 °C under high pressure for 60 min. After cooling, add it to the culture medium after the first stage of culture at a ratio of 8%, and maintain the culture at 37 °C for 36 hours as the condition of the second stage of culture. After the culture is completed, filter out the solid matter with a suction filter, and freeze-dry the solid matter to obtain the spores of Clostridium hiranonis as the finished product of the Clostridium hiranonis microecological preparation.
[0032] Clinical effect test
[0033] Since there is no conclusive conclusion on the formation mechanism of chronic enteropathy in pets in the current academic community, and there is no uniformly recognized scheme for the construction of chronic enteropathy models in pets, the effect test of this implementation plan is carried out from the perspective of actual performance; pets suffering from chronic enteropathy will show symptoms of long-term persistent diarrhea and severe protein loss, and their body weight will decrease significantly. In this test, 16 dogs diagnosed with chronic enteropathy and without other underlying diseases are selected. During the home stage, the feeding plan before the onset is maintained, and at the same time, the test is carried out by orally administering one tablet of Clostridium hiranonis preparation per 5 kg of body weight per day. The effect is evaluated by statistically analyzing the changes in fecal moisture and body weight.
[0034] The fecal moisture evaluation method is scored and evaluated according to the WALTHAM fecal scoring standard (reference Figure 1 )
[0035]
[0036]
[0037] Body weight change
[0038]
[0039]
[0040] Fecal moisture score
[0041]
[0042]
[0043] According to the data in the above table, intuitively, the diarrhea symptoms of the test animals have been alleviated to varying degrees, which can directly reflect that their intestinal functions have been improved to varying degrees. Since the absorption and metabolism functions of the intestine for nutrients have been improved, it has led to the alleviation of the malnutrition caused by diseases in the test animals for a long time, and their weights have increased to varying degrees. Therefore, from the perspective of the actual application effect, this implementation plan has a positive effect on dogs suffering from chronic intestinal diseases.
[0044] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to the preferred embodiments, those of ordinary skill in the art should understand that the technical solutions of the present invention can be modified or equivalently replaced without departing from the spirit and scope of the technical solutions of the present invention, and they should all be covered within the scope of the claims of the present invention.
Claims
1. A microbial preparation for treating inflammatory bowel disease, characterized in that The invention is prepared from the following raw materials in parts by weight: 3-5 parts of Clostridium hiranoensis microecological preparation, 30-35 parts of enzymatically hydrolyzed chicken liver powder, 10-15 parts of glutamine, 8-10 parts of oligofructose, 10-15 parts of β-1,3-D-glucan, 39.5-40 parts of maltodextrin, 0.2-0.5 parts of silicon dioxide and 0.5-1 parts of magnesium stearate; The Clostridium hirano was a Clostridium hirano strain purchased from Guangdong Provincial Microbiological Culture Collection Center with a collection number of GDMCC1.1530.
2. The microbial preparation for treating inflammatory bowel disease according to claim 1, characterized in that: The Clostridium hirano strain is cultured under anaerobic conditions using a PY medium containing glucose.
3. The microbial preparation for treating inflammatory bowel disease according to claim 2, characterized in that: The glucose-containing PY medium is prepared according to the following proportions: 20 parts of polyvalent peptone, 5 parts of yeast extract, 5 parts of sodium chloride, 5 parts of glucose and 1000 parts of water, and the pH value is adjusted to 6.8-7.
0.
4. The microbial preparation for treating inflammatory bowel disease according to claim 3, characterized in that: After the glucose-containing PY medium is prepared, it is heated to dissolve evenly and then sterilized at 121° C. under high pressure for 15 minutes. After cooling to 37° C., it is inoculated with Clostridium hirnoensis (GDMCC1.1530), and then the temperature is maintained at 37° C. and cultured under anaerobic conditions for 48 hours. After the culture is completed, PYG medium is used for expansion.
5. The microbial preparation for treating inflammatory bowel disease according to claim 4, characterized in that: The PYG medium is prepared according to the following proportions: 20 parts of peptone, 5 parts of glucose, 10 parts of yeast extract powder, 0.08 parts of sodium chloride, 0.5 parts of cysteine hydrochloride, 0.008 parts of calcium chloride, 0.008 parts of magnesium sulfate, 0.008 parts of potassium dihydrogen phosphate, 0.4 parts of sodium bicarbonate and 520 parts of water, and the pH value is adjusted to 7.1-7.
3. After the preparation of the PYG medium, it is sterilized under high pressure conditions at 115° C. for 15 minutes, cooled to 50° C. for standby use.
6. The microbial preparation for treating inflammatory bowel disease according to claim 5, characterized in that: The vitamin K1 ethanol solution and the hemin solution are added to the PYG culture medium at 50°C in a ratio of 0.5ml of the vitamin K1 ethanol solution and 2.5ml of the hemin solution for every 556.1g of the PYG culture medium, and the mixture is evenly mixed, and then cooled to 37°C. The culture of Clostridium hirano in the PY culture medium is transferred into the PYG culture medium mixed with the vitamin K1 ethanol solution and the hemin solution, and then a two-stage culture is carried out. The first stage condition is to control the temperature to 37°C and maintain anaerobic conditions for 72 hours.
7. The microbial preparation for treating inflammatory bowel disease according to claim 6, characterized in that: The vitamin K1 ethanol solution is prepared by weighing vitamin K1 and anhydrous ethanol in a mass ratio of 1:78, and filtering and sterilizing the solution after dissolution for later use.
8. The microbial preparation for treating inflammatory bowel disease according to claim 7, characterized in that: The hemin solution is prepared by weighing 1 part of hemin and dissolving it in a sodium hydroxide solution with a concentration of 1 mol / L, which is twice the mass of the hemin, adding 100 parts of distilled water, sterilizing it under high pressure at 121° C. for 15 minutes, and then cooling it for use.
9. The microbial preparation for treating inflammatory bowel disease according to claim 8, characterized in that: The rice husk powder is sterilized at 121° C. under high pressure for 60 minutes, and after cooling, it is added to the culture solution after the first stage of culture at a ratio of 8%, and the culture is maintained at 37° C. for 36 hours as the condition for the second stage of culture. After the culture is completed, the solids are filtered out by a suction filter, and the solids are freeze-dried to obtain the spores of Clostridium hirano as the finished product of the Clostridium hirano microecological preparation.
10. The method for preparing a microbial preparation for treating inflammatory bowel disease according to claim 9, characterized in that The Clostridium hirano microecological preparation, enzymatic chicken liver powder, glutamine, oligofructose, β-1,3-D-glucan, maltodextrin, silicon dioxide and magnesium stearate are mixed, and then granulated and dried, and then tableted using a tablet press to obtain a microbial preparation for treating inflammatory bowel disease.
